Literature DB >> 29017855

Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice.

Hitoshi Teranishi1, Masafumi Hayashi2, Ryoko Higa3, Kenji Mori4, Takashi Miyazawa5, Jun Hino4, Yuichiro Amano6, Ryuichi Tozawa6, Takanori Ida7, Toshikatsu Hanada3, Mikiya Miyazato4, Reiko Hanada8, Kenji Kangawa4, Kazuwa Nakao5.   

Abstract

Neuromedin U (NMU), a neuropeptide originally isolated from porcine spinal cord, has multiple physiological functions and is involved in obesity and inflammation. Excessive fat accumulation in the liver leads to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which is closely associated with obesity. NAFLD and NASH develop and progress via complex pathophysiological processes, and it remains unclear to what extend the NMU system contributes to the risk of obesity-related disorders such as NAFLD and NASH. Here, we demonstrate that the NMU system plays a role in NAFLD/NASH pathogenesis. In the normal mouse liver, NMU mRNA was not detectable, and expression of the mRNA encoding neuromedin U receptor 1 (NMUR1), the peripheral receptor of NMU, was low. However, the expression of both was significantly increased in the livers of NASH mice. Furthermore, overproduction of NMU induced the mouse liver by hydrodynamic injection, exacerbated NASH pathogenesis. These data indicate a novel role for the peripheral NMU system, providing new insights into the pathogenesis of NAFLD/NASH.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; NAFLD/NASH; Neuromedin U; Obesity-related disease

Mesh:

Substances:

Year:  2017        PMID: 29017855     DOI: 10.1016/j.peptides.2017.09.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target.

Authors:  Wonbeak Yoo; Jaemin Lee; Eunsung Jun; Kyung Hee Noh; Sangmin Lee; Dana Jung; Kwang Hwa Jung; Ji-Su Kim; Yun-Yong Park; Song Cheol Kim; Seokho Kim
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

Review 2.  Neuromedin U, a Key Molecule in Metabolic Disorders.

Authors:  Hitoshi Teranishi; Reiko Hanada
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 3.  Neuromedin U: potential roles in immunity and inflammation.

Authors:  Yuan Ye; Zongan Liang; Luzheng Xue
Journal:  Immunology       Date:  2020-09-16       Impact factor: 7.397

4.  Identification of Potential Biomarkers for Thyroid Cancer Using Bioinformatics Strategy: A Study Based on GEO Datasets.

Authors:  Yujie Shen; Shikun Dong; Jinhui Liu; Liqing Zhang; Jiacheng Zhang; Han Zhou; Weida Dong
Journal:  Biomed Res Int       Date:  2020-04-01       Impact factor: 3.411

5.  The prognostic value of neuromedin U in patients with hepatocellular carcinoma.

Authors:  Qiao Li; Lingyu Han; Shengnan Ruan; Shunli Shen; Qinghua Cao; Xiuqin Cai; Yuan Yan; Baogang Peng; Yunpeng Hua
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.